Drs. Meloni and Bogin were invited to discuss Nobilis Therapeutics’ PTSD clinical development program in front of the US Congress. As treatment for PTSD remains a tremendous unmet need, there is a significant interest on the part of the Congress, VA, DoD and other agencies to make sure that the best drug candidates have every chance to make it through clinical testing.
After a very positive pre-IND meeting the Company is getting ready to file an IND for its phase IIb-III clinical trial where its leading drug-device combination, NBTX-001 will be tested against placebo. Given very strong preclinical data and encouraging results of its ex-US Panic Disorder study the Company is very optimistic about this upcoming trial.
Please stay tuned for more exciting news from Nobilis Therapeutics!
